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Introduction
Asthma is a complex inflammatory disease that
afflicts nearly 15 million Americans. Despite research
advances, the worldwide prevalence, morbidity, and
mortality of asthma have increased over the last two
decades (1–3). In humans, the hallmark feature of
allergic asthma is the abnormal expansion in the lung
of Th cells that produce Th2 cytokines. This patho-
logical event leads to the symptoms of asthma includ-
ing airway inflammation, airway hyperresponsiveness,
reversible airflow obstruction, and airway remodeling.
Like other immune cells, T cells are functionally
dependent on their ability to migrate, localize within
tissues, and interact with other immune cells (4).
Chemotaxis, the process by which immune cells
migrate, is mediated by chemokine activation of
chemokine receptors (5).
Chemokine receptors are part of the enormous fam-
ily of heptahelical cell surface receptors known as G
protein–coupled receptors (GPCRs) (6). These recep-
tors transduce extracellular signals into intracellular
events by activating heterotrimeric G proteins. The
dissociation of these G protein subunits activates cell
signaling systems such as adenylate cyclases, phos-
pholipases, and ion channels, which ultimately results
in a physiological response. In the case of chemokine
receptors, at least one of these physiological respons-
es is cell migration.
Like other GPCRs, chemokine receptor function is
regulated by β-arrestin proteins. β-arrestins, members
of the arrestin family of proteins, are designated β-
arrestin-1 or β-arrestin-2, are ubiquitously expressed,
and regulate GPCR function through multiple mech-
anisms (7–9). As their name suggests, β-arrestin pro-
teins were originally discovered to “arrest” G pro-
tein–mediated cell signaling events (10). Since that
time, our understanding of the mechanisms by which
β-arrestin modulates GPCR function has expanded
considerably. In addition to their classical role, β-arrestin
proteins also act as adapters that couple GPCRs to a
clathrin-coated pit endocytic mechanism and as scaf-
folds that link GPCRs to a second wave of cell signal-
ing via MAPK and other signaling pathways.
In vitro studies have shown that lymphocytes devoid
of β-arrestin-2 and human embryonic kidney 293 cells
with suppressed expression of β-arrestin-2 demon-
strate impaired migration toward the chemotactic fac-
tor stromal cell–derived factor-1α (SDF-1α), also
known as CXCL12 (11, 12). Although β-arrestin-2 is
essential to the normal migration of immune cells in
vitro, the ability of β-arrestin-2 to mediate immune
cell chemotaxis in vivo has not been tested.
Because chemotaxis is crucial to the process of inflam-
mation, we theorized that mice lacking β-arrestin-2
might be protected from developing allergic-asthmatic
inflammation. To model allergic asthma in mice we
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used a standard method consisting of sensitization and
challenge to OVA (13). This mouse model of allergic
asthma mimics several features of human asthma.
Methods
Animals. Male and female β-arrestin-2–deficient
(βarr2–/–) (14) and littermate WT mice (backcrossed
for six generations onto the C57BL/6 background)
were used for all experiments at 8–12 weeks of age. All
experiments were conducted in accordance with NIH
guidelines for the care and use of animals and with
approval from the Duke University Animal Care and
Use Committee.
Immunization and airway challenge. Mice were immu-
nized intraperitoneally on days 0, 7, and 14 with 10 µg
grade V OVA (Sigma-Aldrich, St. Louis, Missouri,
USA) adsorbed to 200 µg of alum adjuvant (Pierce
Biotechnology Inc., Rockford, Illinois, USA) diluted
in saline. Sham-immunized animals received 200 µg
of saline-diluted alum intraperitoneally. Secondary
challenge consisted of a 60-minute exposure to 1%
(wt/vol) OVA in saline on days 21, 22, and 23. All mice
were exposed to aerosol in a 60-l exposure chamber
connected to the outlet of a six-jet atomizer that deliv-
ered an aerosol of particles with a mean diameter of
0.3 µm (TSI Inc., St. Paul, Minnesota, USA). The term
“OVA treatment” is used hereafter to refer to mice
treated according to the OVA sensitization and OVA
aerosol challenge protocol described above.
Endotoxin exposures. LPS for aerosolization was pur-
chased as lyophilized purified Escherichia coli 0111:B4
(Sigma-Aldrich). LPS was solubilizedin sterile saline to
a concentration of 5 mg/ml, stored at –20°C, and
diluted further in saline to the appropriate concentra-
tion on the day of the experiment. LPS was aerosolized
with a six-jet atomizer (TSI Inc.) that generated parti-
cles with a mean diameter of 0.3 µm, and directed into
a 60-l exposure chamber for 2.5 hours. At regular inter-
vals, LPS concentrations were determined by sampling
the aerosol through a side port on the chamber. Endo-
toxin concentrations were assayed with the chro-
mogenic Limulus amebocyte lysate assay (BioWhittak-
er Inc., Walkersville, Maryland, USA) as previously
described (15). The average endotoxin concentration
used was 5.53 ± 0.5 µg/m3.
Airway responsiveness. The day after the final aerosol
challenge, airway responsiveness to methacholine was
measured as previously described (16). In brief, mice
were anesthetized with an intraperitoneal injection of
pentobarbital sodium (60 mg/kg) diluted 50% with
saline and then surgically prepared with a tracheal
cannula and a jugular vein catheter. Mice were para-
lyzed with doxacurium chloride (0.25 mg/kg) and
ventilated with 100% oxygen at a constant volume of
8–10 ml/kg and a frequency of 125 breaths/min.
These ventilator settings resulted in an average rest-
ing peak airway pressure of 7.8 ± 0.2 cm H2O and have
been previously shown to provide normal arterial
blood gases. Measurement of airway pressure was
made at a side port of the tracheal cannula connected
to a Validyne differential pressure transducer (Vali-
dyne Engineering, Northridge, California, USA). The
time-integrated change in peak airway pressure, or air-
way pressure time index (17), was calculated for a 30-
second period beginning immediately after metha-
choline injection.
Whole-lung lavage. After in vivo measurements, mice
were sacrificed by sodium pentobarbital overdose.
Lungs were lavaged as previously described (15).
Differential cell counts were performed on cytospin
preparations (Cytospin 2; Thermo Shandon, Pitts-
burgh, Pennsylvania, USA) stained using Hema-3
staining kit (Fisher Scientific, Springfield, New Jer-
sey, USA) and 200 cells were classified using stan-
dard morphologic criteria. Lavage fluid cytokine
levels were determined in lavage fluid using com-
mercially available cytokine ELISA kits (Quantikine;
R&D Systems Inc., Minneapolis, Minnesota, USA).
The detection limits were as follows: IL-4 (2 pg/ml),
IL-5 (7 pg/ml), IL-13 (1.5 pg/ml), IL-12 (< 4 pg/ml),
IFN-γ (< 2 pg/ml), and macrophage-derived chemo-
kine (MDC) (< 5 pg/ml).
Serum Ig titers. At three timepoints in the sensitiza-
tion protocol (day 10, day 17, and after in vivo meas-
urements on day 24), blood was harvested from the
inferior vena cava of βarr2–/– and WT mice. Serum was
separated by centrifugation and stored at –20°C until
analyzed. OVA-specific serum IgE, IgG1, and IgG2a lev-
els were determined using ELISA methodology and
geometric mean titer analysis. Briefly, 96-well plates
(NUNC MaxiSorp; Nalge Nunc International, Neeri-
jse, Belgium) were coated with 100 µl/well of 100
µg/ml OVA (Sigma-Aldrich) in 0.1 M carbonate coat-
ing buffer (pH 9.6) and incubated overnight at 4°C.
The wells were washed with 0.5% Tween 20/PBS and
blocked with 1% BSA/PBS, which also served as the
assay diluent. After 1.5 hours, wells were washed three
times and samples (serially diluted 1:2 twelve times,
beginning with 1:64) were added across the plate and
incubated for 1.5 hours at 37°C. After washing, the
primary antibody (sheep anti-mouse IgE from Cal-
biochem-Novabiochem Corp., San Diego, California,
USA) was added and samples were incubated a further
1.5 hours, washed, and incubated a second time with
the detection antibody (peroxidase-conjugated rabbit
anti-sheep IgG from Calbiochem-Novabiochem Corp.).
For detection of OVA-IgG1, the primary antibody was
biotin-conjugated anti-mouse IgG1 with avidin-HRP
at 2.5 µg/ml (A3151; Sigma-Aldrich). For detection of
OVA-IgG2a, the primary antibody was HRP-conjugat-
ed anti-mouse IgG2a (BD Pharmingen, San Diego,
California, USA). After a further wash, all plates were
developed with tetramethylbenzidine substrate solu-
tion, stopped with 2 N H2SO4, and read at 450 nm.
Naive serum from nonsensitized C57BL/6J mice was
assayed on each plate to calculate a standard curve,
and titers were calculated at twofold over the asymp-
tote of the naive curve.
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Isolation of lymphocytes. All lymphocyte isolation
was carried out in polypropylene tubes. Spleens
were isolated from OVA-treated mice and disrupted
in a dounce homogenizer in 1 ml RPMI 1640 medi-
um (Invitrogen Corp., Gaithersburg, Maryland,
USA). Following centrifugation at 370 g for 10 min-
utes, rbc’s were lysed in lysis buffer (0.14 M NH4Cl
and 0.017 M Tris, pH 7.4) and the cells were pellet-
ed. The cells were washed in RPMI, filtered through
a 70-µm BD Falcon strainer (Becton, Dickinson and
Co.), and counted.
Lungs were isolated and disrupted in HBSS con-
taining 0.5 U/ml heparin through a 200-gauge stain-
less steel mesh. Lymphocytes from either OVA-treat-
ed WT or OVA-treated βarr2–/– mice were pooled. The
cells were centrifuged at 370 g for 10 minutes at 4°C
and resuspended in 15 ml of a 33% Percoll solution
(Sigma-Aldrich) diluted in HBSS containing 100
U/ml heparin. The cells were centrifuged at 500 g for
15 minutes at room temperature. The pelleted cells
were resuspended in lysis buffer to remove red blood
cells. The cells were then washed in HBSS, resuspend-
ed in RPMI containing 10% FBS, and counted.
Chemotaxis assays. Splenocytes (1 × 106) or lung lym-
phocytes (1 × 105) were placed in 100 µl RPMI con-
taining 10% FBS in the upper chamber of a Transwell
insert (6.5 mm diameter, 5-µm pore size; Corning
Costar Corp., Acton, Massachusetts, USA). The lower
chamber contained 100 nM MDC (R&D Systems
Inc.) in 600 µl RPMI prepared with 10% FBS. After
incubation at 37°C for 90 minutes, the migrated cells
were collected from the lower chamber. The cells were
stained with the following antibodies: 17A2-FITC
(anti-CD3, BD Pharmingen), GK1.5-phycoerythrin
(anti-CD4, BD Pharmingen), and anti-CD45R–tri-
color (Caltag Laboratories Inc., Burlingame, Califor-
nia, USA). Cells were then analyzed using a Coulter
Epics XL flow cytometer (Coulter Electronics Ltd.,
Hialeah, Florida, USA). The chemotactic index was
calculated as the number of cells migrating toward
MDC/number of cells migrating to medium alone.
All assays were performed in duplicate. βarr2–/– mice
and their littermate-matched controls were tested
simultaneously.
Histopathology. Immediately after collection of lavage
fluid, ice-cold 4% paraformaldehyde (Fisher Scientif-
ic Co., Pittsburgh, Pennsylvania, USA) in 1× PBS (pH
7.4) was instilled through the tracheal cannula at a
constant pressure of 25 cm H2O to inflation-fix the
lung. Specimens were immersed in 4% paraformalde-
hyde at 4°C overnight and dehydrated in a graded
series of ethanol solutions. Tissue was embedded in
paraffin. Sections were cut at 5 µm thickness and
mounted onto positively charged slides (Super Frost
Plus; Fisher Scientific Co.). For determination of
inflammatory cells, H&E-stained slides were semi-
quantitatively scored in a blinded fashion. For deter-
mination of CD3+ T cells, tissue sections underwent a
high-temperature antigen-unmasking procedure as
follows. After dewaxing and rehydration, the sections
were immersed in 1.6 l of 1 mM EDTA, pH 8.0, in a
pressure cooker that was then closed and slowly, over
a period of 3–4 minutes, brought to boiling tempera-
ture. After a total time of 5 minutes, the pressure
cooker was cooled under running tap water and
opened, and the slides were transferred to PBS (pH
7.5) and rested at room temperature for 5 minutes.
Endogenous peroxidase was destroyed with 0.3%
H2O2 for 30 minutes at room temperature, followed
by a rinse in blocking normal rabbit serum. The pri-
mary antibody used was a rat monoclonal anti-CD3
antibody from Novocastra Laboratories Ltd. (New-
castle, United Kingdom). Slides were incubated with
either active antibody (1:250) or with normal rat IgG
as a negative control. The secondary antibody was
biotin-conjugated rabbit anti-rat IgG (Vector Labora-
tories Inc., Burlingame, California, USA), addition of
which was followed by treatment with standard
avidin-biotin HRP. Peroxidase activity was detected
with 3,3′-diaminobenzidine (DAB; Vector Laborato-
ries Inc.) and hydrogen peroxide, after which a hema-
toxylin counterstain was performed.
Statistical analysis. Multivariate ANOVA was used to
determine differences in airway responsiveness. A Stu-
dent t test was used to determine differences when
only two experimental groups existed. Otherwise, a
one-way ANOVA, in combination with a Tukey hon-
estly significant difference (HSD) post-hoc test, was
used to determine differences among groups. For all
tests, P < 0.05 was considered significant.
Results
To examine the role of β-arrestin-2 in the pathogene-
sis of asthma, we used an OVA model of allergic asth-
ma and an endotoxin model of nonallergic asthma.
We measured physiological and biological variables
including airway responsiveness, airway inflammato-
ry cell infiltration, T cell chemotaxis, cytokine levels
in whole-lung lavage fluid, and serum Ig levels.
Airway responsiveness. OVA treatment resulted in a
dramatic increase in airway responsiveness in WT
mice (Figure 1) as measured by airway pressure time
index. In marked contrast, βarr2–/– mice treated with
OVA (βarr2–/–-OVA mice) showed no such increase in
airway responsiveness compared with either WT-alum
or βarr2–/–-alum (control) mice.
Lung inflammation. Histological analysis showed that
only mild extravasation of inflammatory cells, includ-
ing CD3+ T lymphocytes, occurred in the airways of
βarr2–/– mice treated with OVA, whereas severe cellu-
lar infiltration occurred in the interstitium of WT-
OVA mice (Figure 2, a and b). Quantitation of CD3+
cells per mm of basement membrane or CD4+ cells
harvested from lung show that βarr2–/– mice experi-
ence significantly reduced T lymphocyte infiltration
into the lung (Table 1). Differential cell counts from
lavage fluid supported the histological data revealing
that lymphocyte and eosinophil infiltration into the
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lungs of βarr2–/–-OVA mice was markedly reduced
compared with WT-OVA mice and was not different
from that in alum-treated control mice of either
genotype (Figure 2c). The lack of T lymphocytes in
the lung of βarr2–/–-OVA mice suggests that the
migration of T cells to the lung is impaired in the
absence of β-arrestin-2.
Cytokine levels. Activated T cells migrate to the lungs
and release inflammatory cytokines to orchestrate the
allergic inflammatory response. Consistent with the
demonstrated lack of lymphocytes in the airways of
βarr2–/–-OVA mice was their diminished level of Th2
cytokines. Analysis of lavage fluid from WT-OVA mice
showed a significant increase in the levels of IL-4, 
IL-5, and IL-13 relative to the respective cytokine level
in lavage fluid from βarr2–/–-OVA mice and alum con-
trols (Figure 3a). To determine whether βarr2–/– mice
have a Th1-skewed response that might inhibit the
development of Th2 lymphocytes, we measured Th1-
type cytokines in lung lavage fluid (18). Levels of IL-12
and IFN-γ were not different between WT and βarr2–/–
mice, and the level of these cytokines was unaffected
by OVA treatment (Figure 3b).
Ig production. The absence of the classic features of
a Th2-mediated asthmatic response in OVA-treated
βarr2–/– mice indicates that β-arrestin-2 exerts its
regulatory effect early in the progression of allergic
asthma. β-Arrestin-2 may regulate the handling of
aeroallergen, a series of events that occurs prior to,
and is necessary for, T cell stimulation and allergen-
specific Ig production. However, the serum levels of
OVA-specific IgE and OVA-specific IgG1 were signif-
icantly elevated in βarr2–/–-OVA mice, and the mag-
nitude of this antigen-specific antibody production
was not significantly different from the response
observed in WT-OVA mice (Figure 4, a and b). Thus,
βarr2–/– mice are competent in their ability to pres-
ent antigen, to generate antigen-specific T cell
responses, and to undergo Ig isotype switching. Mea-
surement of IgG2a, a serum Ig typical of a Th1-type
response, was not different between WT and βarr2–/–
mice (Figure 5, a and b). These data show that the
lack of a Th2-type response in βarr2–/– mice is not
due to enhanced induction of the Th1 arm of the Th
cell pathway for development.
CD4+ T cell chemotaxis. In allergic asthma, MDC is a
potent Th2 cell chemoattractant produced by acti-
vated lung macrophages, airway smooth muscle cells,
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Figure 1
Effect of OVA treatment on airway responsiveness. Airway respon-
siveness to methacholine, defined by the time-integrated change in
peak airway pressure, or airway pressure time index (APTI), was
measured for βarr2–/– (circles) and WT (squares) mice treated with
either alum (filled symbols) or OVA (open symbols). Data are mean
± SEM; n = 9–12 mice per group. *Effect of OVA treatment was sig-
nificantly different between WT and βarr2–/– mice. P < 0.05.
Figure 2
Effect of OVA treatment on airway inflammation. (a) Effect of genotype and OVA treatment on lung inflammation evaluated by histo-
logical analysis of lung sections. Lung sections from WT-alum (lower left) and βarr2–/–-alum mice (lower right) appeared normal with
no inflammatory cell infiltration. Lung sections from WT-OVA mice (upper left) showed severe cellular infiltration in the interstitium.
Lung sections from βarr2–/–-OVA mice (upper right) showed mild extravasation of inflammatory cells in the interstitium. Representa-
tive histological sections are shown (n = 8–11 mice per group). (b) Representative images of cross-sectioned airways together with peri-
bronchovascular connective tissue are shown. CD3+ T cells were counted in the subtended bronchovascular interstitium. OVA-treated
WT mice showed an increased number of CD3+ T cells in the peribronchovascular zone relative to alum-treated mice. No such infiltra-
tion of CD3+ T cells was observed in OVA-treated βarr2–/– mice. (c) Effect of genotype and OVA treatment on lung inflammation assessed
by identification of cells harvested from whole-lung lavage. Black bars represent WT-OVA mice; white bars represent βarr2–/–-OVA mice;
light gray bars represent WT-alum mice; dark gray bars represent βarr2–/–-alum mice. Data are mean ± SEM; n = 9–12 mice per group.
*P < 0.05 versus all other groups.
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bronchiolar epithelial cells, and by Th2 cells them-
selves (5). To investigate whether CD4+ T cell migra-
tion to the lung is impaired in βarr2–/– mice, we test-
ed the ability of splenocytes, thoracic lymph node
cells, and lung lymphocytes from OVA-treated WT
and βarr2–/– mice to respond to MDC. Only lung lym-
phocytes, and not spleen or lymph node T cells (data
not shown), migrated toward MDC. While CD4+ T
cells harvested from lung of OVA-treated WT mice
migrated well toward MDC, CD4+ T cells lacking β-
arrestin-2 were significantly impaired in their migra-
tion toward MDC (Figure 6a). MDC levels in lavage
fluid were significantly elevated in OVA-treated WT
mice, but not in similarly treated βarr2–/– mice (Fig-
ure 6b). These data support the notion that β-
arrestin-2 positively regulates MDC-mediated CD4+
T cell migration to the lung in OVA-treated mice.
However, β-arrestin-2 may alternatively, or addition-
ally, regulate CD4+ T cell migration in response to a
chemokine other than MDC.
Nonallergic asthma model. To further investigate the
specificity of the impaired asthmatic response in
βarr2–/– mice, we subjected mice to a model of endo-
toxin-mediated asthma, or nonallergic asthma.
Endotoxin, an LPS, is a major component of the
outer cell membrane of all gram-negative bacteria,
and even small amounts of this molecule are
immune-stimulatory (19). Subjects with endotoxic
asthma demonstrate lung neutrophilic inflamma-
tion and airway hyperresponsiveness, and this
response is coordinated by alveolar macrophages and
epithelial cells rather than T cells (20). Both WT and
βarr2–/– mice exposed to aerosolized LPS developed
lung neutrophilic inflammation and increased air-
way responsiveness (Figure 7, a and b). Thus, there is
no general impairment of lung inflammatory
processes or in the ability of airways to respond to
methacholine in βarr2–/– mice.
Discussion
When treated with OVA, WT mice develop symptoms
of allergic asthma. In stark contrast, these symptoms,
including airway inflammation and airway hyperre-
sponsiveness, do not appear in similarly treated
βarr2–/– mice. These results suggest that β-arrestin-2
is essential to the development of allergic asthma and
that it exerts its regulatory effect at a proximal step in
the inflammatory cascade.
Numerous immune cell types, including APCs, T
lymphocytes, B lymphocytes, eosinophils, and mast
cells, interact in a highly coordinated fashion to
respond to allergens. Although the nature and
sequence of these interactions are not entirely delin-
eated, the infiltration of activated Th2 cells into the
lung is a primary pathological event underlying aller-
gic asthma. Without these cells, the symptoms of
asthma, including airway inflammation, airway
hyperresponsiveness, and reversible airflow obstruc-
tion, do not occur (21–23).
Table 1
Quantitation of T lymphocytes in the lung
CD3+ cells per mm CD4+ T cells 
basement membrane harvested from lung
WT-OVA 31.04 ± 1.36* 21,400/lung
βarr2–/–-OVA 2.08 ± 1.57 6,900/lung
WT-alum 2.96 ± 0.85
βarr2–/–-alum 2.21 ± 0.74
Using calibrated digital images, the perimeter of the bronchiolar basal lam-
ina of each histological profile (represented in Figure 2b) was traced and the
length was measured. The results were expressed as the number of CD3+ T
cells per mm of airway basal lamina for each profile. To quantitate the num-
ber of CD4+ T cells, lungs from OVA-treated mice were processed and cells
were identified using GK1.5-phycoerythrin (anti-CD4) and FACS analysis.
The mean ± SEM for each treatment/genotype group is shown; n = 7–10
mice per group. *P < 0.05 versus all other groups.
Figure 3
Effect of genotype and OVA treatment on lung cytokine release in
whole-lung lavage fluid. (a) Cytokines associated with a Th2-type
response were significantly elevated in WT-OVA mice relative to
βarr2–/–-OVA mice and alum-treated mice of either genotype. Black
bars represent WT-OVA mice; white bars represent βarr2–/–-OVA
mice. Cytokine levels in alum-treated WT and alum-treated βarr2–/–
mice were not different and therefore were combined as shown by
gray bars. Data are mean ± SEM calculated from three independ-
ent experiments; n = 11–19 mice per group. *P < 0.05 versus all
other groups. (b) Cytokines associated with a Th1-type response
were not significantly elevated by OVA treatment and were similar
for WT and βarr2–/– mice. Black bars represent WT-OVA mice;
white bars represent βarr2–/–-OVA mice. Light gray bars represent
alum-treated WT mice; dark gray bars represent βarr2–/– mice.
Data are mean ± SEM calculated from two to three independent
experiments; n = 7–13 mice per group.
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The initial event in the development of allergic
asthma is the processing of inhaled allergens. This
involves the capture, modification, and presentation
of allergen to T and B cells (24). Once activated, T
cells proliferate and differentiate to a Th2 phenotype
defined by the release of type 2 cytokines (IL-4, IL-5,
IL-6, IL-9, IL-10, and IL-13). Release of these
cytokines at germinal centers within peripheral lym-
phoid tissue supports B cell–mediated production of
allergen-specific antibodies (25, 26). In addition, type
2 cytokines released from T cells that have migrated
to the lung activate and recruit mast cells and
eosinophils, the primary effector cells of the allergic
asthmatic response (1).
Our study shows that antigen processing, presenta-
tion, and activation of T cells are intact in βarr2–/–
mice since their serum levels of OVA-specific IgE and
IgG1 are comparable to those in WT mice and are sig-
nificantly elevated compared with alum-treated mice.
Although there is a trend for a slight delay in the
kinetics of the Ig response in OVA-treated βarr2–/–
mice, the impact of this on the physiological and bio-
logical measurements made on day 24, when OVA-IgE
levels are the same, is unknown. Despite the signifi-
cant production of OVA-IgE and OVA-IgG1 in OVA-
treated βarr2–/– mice, the classic features of a Th2-
mediated asthmatic response, including airway in-
flammation, airway hyperresponsiveness, and elevat-
ed Th2 cytokines, are absent in these mice. Therefore,
the defect in the allergic asthmatic response in
βarr2–/– mice lies between the generation of a Th2
response and airway inflammation. Our data show-
ing defective CD4+ T cell migration to the Th2
chemoattractant MDC and reduced levels of MDC in
lavage fluid suggests that the defect is present at the
level of Th2 cell trafficking to the lung.
Other potential mechanisms underlying the phe-
notype observed in βarr2–/– mice have been evaluat-
ed but ruled out. Other studies have shown that
enhanced induction of Th1-type cytokines may
inhibit the development of a Th2-type response
(18). In our study we find no evidence that βarr2–/–
mice experience Th1-type inhibition of their Th2-
type response since IgG2a, IL-12, and IFN-γ (factors
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Figure 4
Effect of OVA treatment on serum Ig production. Although OVA-
specific IgE (a) and IgG1 (b) levels changed significantly over time,
serum Ig levels in WT-OVA mice (black bars) were not significantly
different from those in βarr2–/–-OVA mice (white bars) when com-
pared at each timepoint (days 10, 17, and 24). These OVA-specif-
ic Ig’s were not detected in alum-treated mice of either genotype.
Measurements were made using the endpoint titer method. Data
are mean ± SD calculated from two independent experiments; 
n = 3–8 mice per group. One-way ANOVA and the Tukey HSD post-
hoc test were used.
Figure 5
IgG2a production. (a) Total serum IgG2a levels were not different
between WT-OVA mice (black bars) and βarr2–/–-OVA mice (white
bars) at day 10, 17, or 24. Similarly, there was no difference in IgG2a
levels in serum from alum-treated WT (light gray bars) and alum-
treated βarr2–/– mice (dark gray bars). Data are mean ± SEM cal-
culated from three independent experiments; n = 4–14 mice per
group. (b) OVA-specific IgG2a measurements were not different
between WT-OVA mice (black bars) and βarr2–/–-OVA mice (white
bars) at day 24. Measurements were made using the endpoint titer
method. Data are mean ± SD calculated from two experiments; 
n = 3 mice per group. ND, non-detectable.
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indicative of a Th1 response) are not elevated in
βarr2–/– mice relative to WT mice.
Another possible explanation for the failure of
βarr2–/– mice to develop asthma is mast cell dysfunc-
tion. Antigen crosslinking of cell-surface IgE receptors
stimulates mast cell release of mediators including
histamine, prostaglandins, leukotrienes, and cyto-
kines. Collectively, these agents perpetuate airway
inflammation and airway hyperresponsiveness and
thus appear pivotal to the development of allergic
asthma (27). However, the ability to respond to OVA
and to develop allergic asthma is preserved in mast
cell–deficient mice (28, 29). Thus, the failure of
βarr2–/– mice to develop asthma cannot be explained
by mast cell dysfunction.
T cell function is crucial to the development of aller-
gic asthma. When T cells are nonfunctional or absent,
allergic inflammation, airway hyperresponsiveness,
and lung cytokine production are prevented in
response to OVA treatment (21–23). These results are
nearly identical to the dramatically impaired allergic
asthmatic response we observed in βarr2–/– mice.
Because βarr2–/– mice have normal levels of CD3+ T
splenocytes (11) and normal architecture of spleen
follicles (data not shown), we suggest that T cell dys-
function, rather than reduction in T cell number, is at
the root of the impaired allergic asthmatic response
in βarr2–/– mice. Since the manifestation of allergic
asthma requires T cell proliferation, differentiation,
and migration, any one of these processes may be reg-
ulated by β-arrestin-2 and thus dysregulated in mice
completely lacking that protein.
We hypothesize that T cell migration is the process
regulated by β-arrestin-2 in allergic asthma. Multiple
in vitro reports demonstrate that β-arrestin regulates
chemokine receptor signaling and internalization
(28, 30, 31). Recently, others in our group used the
chemokine SDF-1α (or CXCL12) to show that
CXCR4-mediated in vitro migration of nonactivated
splenic T cells is impaired in cells lacking β-arrestin-
2 (11). In two separate studies, Gonzalo et al. showed
that lung inflammation and airway hyperrespon-
siveness are significantly reduced when SDF-1α or
MDC are neutralized by antibodies (32, 33). Thus,
reduced migration of activated T cells to SDF-1α may
Figure 6
Chemotactic responses to MDC and release of MDC in lavage
fluid. (a) Lung CD4+ T cells from OVA-treated βarr2–/– mice (white
bars) exhibit decreased migration toward MDC. CD4+ T cells were
isolated on day 24 of the OVA treatment protocol and tested for
their ability to move chemotactically toward 100 nM MDC. Shown
is the mean chemotactic index and SE from three independent
experiments. *P < 0.05 vs. βarr2–/–-OVA mice. (b) Release of MDC
into whole-lung lavage fluid was significantly induced in OVA-
treated WT mice (black bars) but not OVA-treated βarr2–/– mice
(white bars). MDC levels in alum-treated WT and alum-treated
βarr2–/– mice were not different and therefore were combined
(gray bars). Data are mean ± SEM calculated from two independ-
ent experiments; n = 9 mice per group. **P < 0.05 versus combined
alum-treated mice.
Figure 7
Effect of LPS treatment on airway responsiveness and inflamma-
tion. (a) Effect of genotype and LPS treatment on lung inflamma-
tion assessed by identification of cells harvested from whole-lung
lavage. Black bars represent WT LPS-treated mice; white bars rep-
resent βarr2–/– LPS-treated mice. Data are mean ± SEM; n = 13–15
mice per group. (b) Airway responsiveness to methacholine, defined
by the time-integrated change in peak airway pressure was meas-
ured for βarr2–/– (circles) and WT (squares) mice treated with LPS
(open symbols) or untreated (filled symbols). Data are mean ±
SEM; n = 13–15 mice per group. *LPS treatment caused a similar
significant increase in APTI in WT and βarr2–/– mice. P < 0.05.
Downloaded on September  5, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/17265
contribute to the phenotype we observed in βarr2–/–
mice. However, in our study, lung SDF-1α was not sig-
nificantly induced by OVA treatment in either βarr2–/–
or WT mice (data not shown). Thus, MDC is more
likely to play a significant role in the development of
asthma in our model. Indeed, we showed that not only
is the MDC signal reduced in βarr2–/– mice, but the
chemotactic response to this signal is also impaired.
Thus, β-arrestin-2 positively regulates MDC-mediated
Th2 cell migration in the context of allergic asthma.
We hypothesize that diminished Th2 cell migration to
the lung is the primary impairment in βarr2–/– mice
and is largely responsible for their protection against
the development of allergic asthma.
The mechanisms by which β-arrestin-2 may regulate
T cell chemotaxis in vivo or in vitro are not presently
defined. β-Arrestin proteins act as scaffolds to link
GPCR activation to at least three MAPK cascades: the
extracellular signal–regulated kinase (ERK) cascade
(34), the JNK-3 cascade (35), and the p38 MAPK cas-
cade (12). A recent report indicates that β-arrestin-2
activation of the p38 MAPK cascade is required for
CXCR4-mediated migration of human embryonic
kidney 293 cells to SDF-1α (12). β-Arrestin-2 may
similarly regulate CCR4, the receptor for MDC,
through mechanisms involving MAPK or other sig-
naling pathways. Although MAPKs regulate the
phosphorylation of nuclear transcription factors,
recent studies indicate that β-arrestin–MAPK scaf-
folds are preferentially targeted to cytosolic substrates
(34–36). Such cytosolic substrates may be proteins
involved in cell chemotaxis. Thus, β-arrestin-2,
through its action as a scaffold protein, may positive-
ly regulate T cell chemotaxis.
Alternatively, in keeping with their classically
described role, β-arrestins may regulate chemotaxis
through termination of chemokine receptor signaling
(9). This signal termination, or chemokine receptor
desensitization, may be crucial to the directional sens-
ing, and thus migration, of T cells.
Although we feel that β-arrestin-2 regulation of T
cell migration is the major mechanism responsible for
the profound protection against allergic asthma
observed in the βarr2–/– mice, β-arrestin-2 regulation
of other T cell functions, or modulation of cells other
than lymphocytes, may make a contribution to the
dramatic phenotype observed in these mice.
β-arrestin-2 could regulate nonhematopoietic cells
in the lung such as airway smooth muscle or airway
epithelial cells. Indeed, levels of MDC in lavage fluid
are reduced in βarr2–/– mice. This may indicate a pos-
itive role for β-arrestin-2 in regulating chemokine
production/secretion by either of these lung cell
types. Alternatively, reduced MDC levels in lavage
fluid may be explained by altered aeroallergen han-
dling in βarr2–/– mice or may be a by-product of
impaired T cell migration, since Th2 cells are known
to produce MDC. Airway responses to methacholine
challenge were not different between βarr2–/– and
WT mice when treated with alum or LPS, suggesting
that β-arrestin-2 does not regulate airway smooth
muscle cell contraction.
β-arrestin-2 may regulate T cell differentiation.
Yamashita et al. showed that T cell antigen recep-
tor–mediated activation of the Ras-ERK1/2 pathway
enhances IL-4 receptor signaling and is required for
the differentiation of naive T cells into Th2 cells (37).
Although neither T cell receptors nor IL-4 receptors
are GPCRs, there is evidence in the literature of β-ar-
restin-2 modulation of non–GPCR-mediated events
through transactivation of nonheptahelical receptors
or through intracellular modulation of downstream
signaling pathways resulting from antigen or cytokine
receptor stimulation (38). Although differentiation of
T cells to the Th2 lineage may be reduced in βarr2–/–
mice, our results suggest that this does not occur dur-
ing the antigen sensitization phase since the release of
IL-4 from Th2 cells is required for the production of
allergen-specific IgE by B cells (39) and this function
is not impaired in βarr2–/– mice.
The fact that LPS-exposed βarr2–/– mice developed
neutrophilic lung inflammation and increased air-
way responsiveness comparable to similarly treated
WT mice demonstrates that there is no universal
impairment in inflammatory cell migration in
βarr2–/– mice. This demonstration of a functionally
intact innate immune system is critical to the pur-
suit of β-arrestin-2 as a potential therapeutic target
for treating allergic asthma.
The absence of β-arrestin-2 prevents the develop-
ment of allergic asthma without compromising the
function of the innate immune system. Regulation of
T cell migration to the lung by β-arrestin-2 is thought
to be the primary mechanism underlying this protec-
tion. Because β-arrestin-2 exerts its regulatory effect
proximal to the recruitment of activated Th2 cells
into the lung it is an attractive therapeutic target for
treating allergic asthma.
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